Nadofaragene firadenovec (Adstiladrin)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 12:35, 26 December 2022 by Jwarner (talk | contribs) (Created page with "==General information== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nadofaragene-firadenovec NCI Drug Dictionary]: A replication-deficient recom...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

General information

From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.

Diseases for which it is used

History of changes in FDA indication

  • 12/16/2022: Initial approval for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)

Also known as

  • Code name: SCH 721015
  • Generic name: nadofaragene firadenovec-vncg
  • Brand name: Adstiladrin, Instiladrin
Retrieved from "https://hemonc.org/w/index.php?title=Nadofaragene_firadenovec_(Adstiladrin)&oldid=65053"